Stay updated on Pembrolizumab & Blinatumomab in ALL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Blinatumomab in ALL Clinical Trial page.

Latest updates to the Pembrolizumab & Blinatumomab in ALL Clinical Trial page
- Check5 days agoChange DetectedNew help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) have been added, and a recruitment status note indicates no longer looking for participants. The Interventions header has been standardized to Intervention/Treatment, and the revision tag has been updated from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check12 days agoChange DetectedThe page's revision label updated from v3.5.4 to v3.5.5, indicating a minor version update to the page's documentation rather than a substantive change to the study content. This update does not modify any study details, eligibility criteria, or results.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe revision label on the page changed from v3.5.3 to v3.5.4. This reflects a minor site revision without altering the displayed content.SummaryDifference0.1%

- Check41 days agoChange DetectedA Publications subsection was added to the Study Record, listing the article 'Immunotherapy in B-Cell Acute Lymphoblastic Leukemia' by Davis KL et al. with DOI 10.6004/jnccn.2025.7067, and noting that publications are automatically filled from PubMed.SummaryDifference0.3%

- Check55 days agoChange DetectedThe page’s footer revision label was updated from v3.5.2 to v3.5.3, reflecting a site/application version change without altering the study details.SummaryDifference0.1%

- Check62 days agoChange DetectedSite revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Blinatumomab in ALL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Blinatumomab in ALL Clinical Trial page.